Sail Biomedicines and J&J partner on in vivo CAR T therapies

July 30, 2026

Sail Biomedicines Inc. has established a strategic collaboration with Johnson & Johnson (J&J) to advance innovative in vivo CAR T therapies for immune-mediated diseases.

BioWorld Science CAR T Collaboration Immune

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Taiwan biotech looks outward in next phase of growth

BioWorld

Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...